258 related articles for article (PubMed ID: 20594164)
1. Angiogenic growth factors and their inhibitors in diabetic retinopathy.
Praidou A; Androudi S; Brazitikos P; Karakiulakis G; Papakonstantinou E; Dimitrakos S
Curr Diabetes Rev; 2010 Sep; 6(5):304-12. PubMed ID: 20594164
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
Simó R; Carrasco E; García-Ramírez M; Hernández C
Curr Diabetes Rev; 2006 Feb; 2(1):71-98. PubMed ID: 18220619
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravitreal bevacizumab on macular thickness: exploring serum and vitreous proangiogenic biomarkers in patients with diabetic macular edema.
Malik TG; Ahmed SS; Gul R; Khalil M; Malik AA; Khan M
Turk J Med Sci; 2018 Aug; 48(4):833-839. PubMed ID: 30119160
[TBL] [Abstract][Full Text] [Related]
4. Effects of angiogenic growth factor combinations on retinal endothelial cells.
Castellon R; Hamdi HK; Sacerio I; Aoki AM; Kenney MC; Ljubimov AV
Exp Eye Res; 2002 Apr; 74(4):523-35. PubMed ID: 12076096
[TBL] [Abstract][Full Text] [Related]
5. [Aging and retinal vascular diseases].
Takagi H
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):207-30; discussion 231. PubMed ID: 17402563
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
7. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles.
Patel JI; Tombran-Tink J; Hykin PG; Gregor ZJ; Cree IA
Exp Eye Res; 2006 May; 82(5):798-806. PubMed ID: 16324700
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
9. [Lifestyle-related diseases and anti-aging ophthalmology: suppression of retinal and choroidal pathologies by inhibiting renin-angiotensin system and inflammation].
Ishida S
Nippon Ganka Gakkai Zasshi; 2009 Mar; 113(3):403-22; discussion 423. PubMed ID: 19348185
[TBL] [Abstract][Full Text] [Related]
10. Antineovascular agents in the treatment of eye diseases.
Eichler W; Yafai Y; Wiedemann P; Fengler D
Curr Pharm Des; 2006; 12(21):2645-60. PubMed ID: 16842164
[TBL] [Abstract][Full Text] [Related]
11. The role of CTGF in diabetic retinopathy.
Klaassen I; van Geest RJ; Kuiper EJ; van Noorden CJ; Schlingemann RO
Exp Eye Res; 2015 Apr; 133():37-48. PubMed ID: 25819453
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis in rheumatoid arthritis.
Maruotti N; Cantatore FP; Crivellato E; Vacca A; Ribatti D
Histol Histopathol; 2006 May; 21(5):557-66. PubMed ID: 16493585
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
14. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy.
Behl T; Kotwani A
Pharmacol Res; 2015 Sep; 99():137-48. PubMed ID: 26054568
[TBL] [Abstract][Full Text] [Related]
15. [Diabetic retinopathy: pathogenesis and therapeutic implications].
Pelikánová T
Vnitr Lek; 2016; 62(7-8):620-8. PubMed ID: 27627088
[TBL] [Abstract][Full Text] [Related]
16. Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61).
Brigstock DR
Angiogenesis; 2002; 5(3):153-65. PubMed ID: 12831056
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects.
Battegay EJ
J Mol Med (Berl); 1995 Jul; 73(7):333-46. PubMed ID: 8520966
[TBL] [Abstract][Full Text] [Related]
18. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
19. Potential therapeutic implications of intracrine angiogenesis.
Re RN; Cook JL
Med Hypotheses; 2007; 69(2):414-21. PubMed ID: 17320306
[TBL] [Abstract][Full Text] [Related]
20. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
